# Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

> **NCT02630693** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 180 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib 100mg
- **DRUG:** Palbociclib 125mg
- **DRUG:** Fulvestrant or Tamoxifen or Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT02630693
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-08
- **Primary completion:** 2018-08-15
- **Final completion:** 2023-11-29
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630693, "Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02630693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*